Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonaprazan vs Esomeprazole for Post-POEM Reflux Esophagitis
NCT06955520Recruiting
- Sponsor
- Asian Institute of Gastroenterology
- Start
- Apr 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of vonoprazan in reflux esophagitis (2 arms), sponsored by Asian Institute of Gastroenterology. Primary endpoint: Endoscopic healing of reflux esophagitis at 8 weeks. Started Apr 2025; status: recruiting.
02
Drugs
vonoprazan
03
Conditions
reflux esophagitis
Beyond the preview
Go deeper on NCT06955520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06955520.